Vir

Nov 10, 2020

•

Sep 30, 2020

Vir Q3 2020 Earnings Report

Reported financial results for the third quarter of 2020 and provided a corporate update.

Key Takeaways

Vir Biotechnology reported $1.9 million in revenues for the third quarter ended September 30, 2020, compared to $1.4 million for the same period in 2019. Net loss for the quarter was $84.6 million, or $0.67 per share, compared to a net loss of $48.3 million, or $4.60 per share for the same period in 2019.

Initiated COMET-ICE, a Phase 2/3 clinical trial evaluating VIR-7831 for early treatment of COVID-19.

An Independent Data Monitoring Committee recommended the global expansion into Phase 3 of the COMET-ICE trial based on a positive evaluation of safety and tolerability data from the Phase 2 lead-in.

Established a strategic manufacturing network to supply millions of doses of SARS-CoV-2 therapeutics upon approval.

Initiated a Phase 2 combination trial of VIR-2218 with PEG-IFN-α for functional cure of HBV-infected patients.